SAN MARINO, Calif.,
March 9, 2011 /PRNewswire/ -- A new
report from VG Energy, a subsidiary of Viral Genetics, Inc.
(Pinksheets: VRAL), is now featured in an article at EnergyBoom.com
(link:
http://www.energyboom.com/biofuels/algal-fuel-vg-energy-study-shows-price-parity-possible-conventional-oil
). The EnergyBoom.com piece is entitled "Algal Fuel: VG Energy
Study Shows Price Parity Possible With Conventional Oil." The
original report was undertaken by biofuels expert John Sheehan, an advisor to Viral Genetics and
VG Energy, and is available for download at:
http://www.vgenergy.net/SheehanBoyceTechNote20110208.pdf.
"The work being undertaken by VG Energy is showing great promise
as a viable and cost effective alternative energy source," said
Viral Genetics' CEO, Haig Keledjian.
"This report by Mr. Sheehan helps to point the way forward for us,
and the coverage from EnergyBoom.com indicates that we are making
progress and garnering attention from industry. Our next steps are
focused on moving from the laboratory to a production setting."
Mr. Sheehan's report indicates that VG Energy's proprietary
technology has the potential to create algal biofuel at prices that
are competitive with current prices for crude oil. The process that
VG Energy and its lead researcher, Dr. M.
Karen Newell Rogers, are using could potentially lower the
cost for algal oil production by significant amounts, making it
comparable with conventional oil. This process results in increased
lipid production in the algae cells as well as increasing the
ability to recycle these cells. The report models several different
production techniques currently in use with their productivity
enhanced by use of VG Energy's compounds through increased lipid
production and recyclability, showing a range of prices at which
algae oil can be produced. VG Energy is planning studies to
demonstrate these yields in practice. Mr. Sheehan is currently the
Biofuels Coordinator in the Institute on the Environment at the
University of Minnesota, and was
previously a project manager at the National Renewable Energy
Laboratory in Golden, CO.
The process that VG Energy uses to boost algal oil production is
a direct result of work undertaken by Dr. Newell Rogers for cancer treatment. This
process, called Metabolic Disruption Technology (MDT), is meant to
disrupt cancer cells' ability to burn fat reserves, making them
more susceptible to traditional treatments. The same technology
appears to also act as a long sought lipid trigger to cause algae
cells to store increased fat, making them more productive as an
energy source. When the process was applied to algae cells in the
lab, extractable lipid, or fat, production was increased by a
minimum of 300%. Additionally, the process enables the cells to
release fats outside the cell walls, making much of the algae
recyclable. The combination of increased lipid production and
recyclability appears to make algae economical as a source for a
potential biofuel. Dr. Newell
Rogers, the Raleigh R. White, Jr. Endowed Professor of
Surgical Research at Texas A&M Health Sciences Center and Scott
and White Hospital in Temple,
Texas, is continuing her research into biofuel
technology.
About VG Energy
VG Energy Inc. is an alternative energy and agricultural biotech
company that is a majority-owned subsidiary of Viral Genetics Inc.,
a biotechnology company researching new treatments and methods of
detection for diseases including cancer, HIV/AIDS and others. Using
its Metabolic Disruption Technology ("MDT"), Viral Genetics' cancer
research led to discoveries with major consequences in a wide
variety of other industries, including bio-fuel and vegetable oils.
VG Energy Inc. holds the exclusive worldwide license to the MDT
patent rights for use in the increase of production of various
plant-derived oils from algae and seeds. Importantly, these pivotal
discoveries promise to allow the biofuel industry to overcome its
major obstacle in the area of production efficiency: namely an
increase in production yields leading to feasible economic returns
on investment allowing renewable biodiesel to be competitive with
fossil fuels. For more information please visit
www.vgenergy.net.
About Viral Genetics, Inc.
San Marino, California-based
Viral Genetics discovers drug therapies. Founded in 1994, the
biotech company is researching treatments for HIV/AIDS, Lyme
Disease, Strep, Staph and drug resistant tumors. A majority-owned
subsidiary called VG Energy (www.vgenergy.net) is dedicated to
exploring biofuel and agricultural applications for one of the
technologies in its licensed portfolio. Online at
www.viralgenetics.com
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that
involve risks and uncertainties associated with financial
projections, budgets, milestone timelines, clinical development,
regulatory approvals, and other risks described by Viral Genetics,
Inc. from time to time in its periodic reports. None of Viral
Genetics' drug compounds are approved by the US Food and Drug
Administration or by any comparable regulatory agencies elsewhere
in the world. While Viral Genetics believes that the
forward-looking statements and underlying assumptions reasonable,
any of the assumptions could be inaccurate, including, but not
limited to, the ability of Viral Genetics to establish the
commercial suitability of the lipid trigger, or of the efficacy of
any of its drug therapies in the treatment of any disease or health
condition, the development of studies and strategies leading to
commercialization of those drug compounds in the United States, the obtaining of funding
required to carry out development plans, the completion of studies
and tests on time or at all, and the successful outcome of such
studies or tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to
be accurate. In light of the significant uncertainties inherent in
the forward-looking statements included herein, the forward-looking
statements should not be regarded as a representation by Viral
Genetics or any other person that the objectives and plans of Viral
Genetics will be achieved.
www.viralgenetics.com
Contact: Haig Keledjian, Viral
Genetics
|
|
info@viralgenetics.com
T: (626) 334-5310
|
|
|
SOURCE Viral Genetics, Inc.